Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 10/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | NMT2 | O60551 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5584679 | 0.85 | F2RL3 (0.39) | F2RL3MKNK1CYP2A6KCNA3NMT2 | |
| SCHEMBL5584256 | 0.83 | CYP2A6 (0.39) | F2RL3MKNK1CYP2A6KCNA3NMT2 | |
| SCHEMBL5584372 | 0.82 | F2RL3 (0.38) | F2RL3MKNK1CYP2A6KCNA3 | |
| SCHEMBL5584540 | 0.81 | ALDH1A1 (0.40) | F2RL3MKNK1CNR2 | |
| SCHEMBL5584486 | 0.80 | F2RL3 (0.37) | F2RL3MKNK1CYP2A6KCNA3 | |
| SCHEMBL14571629 | 0.77 | SIGMAR1 (0.39) | — | |
| Hydrochloric Acid SCHEMBL5584917 | 0.77 | SIGMAR1 (0.39) | — | |
| SCHEMBL14571627 | 0.76 | SIGMAR1 (0.40) | — | |
| Hydrochloric Acid SCHEMBL5584325 | 0.75 | SIGMAR1 (0.39) | — | |
| SCHEMBL14571630 | 0.74 | SIGMAR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | F2RL3 3870/4885MKNK1 2889/4885CYP2A6 956/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | F2RL3 3870/4885MKNK1 2889/4885CYP2A6 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.